Cargando…

Alpha-Synuclein and the Endolysosomal System in Parkinson’s Disease: Guilty by Association

Abnormal accumulation of the protein α- synuclein (α-syn) into proteinaceous inclusions called Lewy bodies (LB) is the neuropathological hallmark of Parkinson’s disease (PD) and related disorders. Interestingly, a growing body of evidence suggests that LB are also composed of other cellular componen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teixeira, Maxime, Sheta, Razan, Idi, Walid, Oueslati, Abid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472725/ https://www.ncbi.nlm.nih.gov/pubmed/34572546 http://dx.doi.org/10.3390/biom11091333

Ejemplares similares

Optimized protocol for the generation of functional human induced-pluripotent-stem-cell-derived dopaminergic neurons
por: Sheta, Razan, et al.
Publicado: (2023)

Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains
por: Bérard, Morgan, et al.
Publicado: (2023)

Aggregation of alpha-synuclein disrupts mitochondrial metabolism and induce mitophagy via cardiolipin externalization
por: Lurette, Olivier, et al.
Publicado: (2023)

A light-inducible protein clustering system for in vivo analysis of α-synuclein aggregation in Parkinson disease
por: Bérard, Morgan, et al.
Publicado: (2022)

The role of the endolysosomal pathway in α-synuclein pathogenesis in Parkinson’s disease
por: Smith, Jessica K., et al.
Publicado: (2023)

Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?
por: Oueslati, Abid
Publicado: (2016)

LRRK2 and the Endolysosomal System in Parkinson’s Disease
por: Erb, Madalynn L., et al.
Publicado: (2020)

Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons
por: Sheta, Razan, et al.
Publicado: (2022)

Photobiomodulation Suppresses Alpha-Synuclein-Induced Toxicity in an AAV-Based Rat Genetic Model of Parkinson’s Disease
por: Oueslati, Abid, et al.
Publicado: (2015)

Postoperative pneumoperitoneum: guilty or not guilty?
por: Lee, Chang Ho, et al.
Publicado: (2012)

Who Are the Guilty?
por: Pearce, J. D. W.
Publicado: (1955)

Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Fan, Tian-Sin, et al.
Publicado: (2021)

The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?
por: Eribo, Osagie A., et al.
Publicado: (2019)

Mitochondrial Complex I deficiency: guilty in Parkinson’s disease
por: Vos, Melissa
Publicado: (2022)

Bench-to-bedside review: Natural killer cells in sepsis - guilty or not guilty?
por: Souza-Fonseca-Guimaraes, Fernando, et al.
Publicado: (2013)

Interaction between Neuromelanin and Alpha-Synuclein in Parkinson’s Disease
por: Xu, Shengli, et al.
Publicado: (2015)

The Identification of Alpha-Synuclein as the First Parkinson Disease Gene
por: Nussbaum, Robert L.
Publicado: (2017)

Not Guilty
por: Driscoll, W. E.
Publicado: (1870)

Role of the humoral immune response during COVID-19: guilty or not guilty?
por: Yaugel-Novoa, Melyssa, et al.
Publicado: (2022)

Dissociative Identity Disorder and the Law: Guilty or Not Guilty?
por: Kabene, Stefane M., et al.
Publicado: (2022)

Transmission of alpha-synuclein in Parkinson’s disease
por: Lee, Virginia M-Y
Publicado: (2013)

Alpha-synuclein spreading in Parkinson’s disease
por: Recasens, Ariadna, et al.
Publicado: (2014)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

Telomeres, Aging and Exercise: Guilty by Association?
por: Chilton, Warrick, et al.
Publicado: (2017)

Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
por: Maraganore, Demetrius M.
Publicado: (2011)

When is asthma not guilty?
por: Al Shamrani, Abdullah, et al.
Publicado: (2021)

Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles
por: Meade, Richard M., et al.
Publicado: (2019)

Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
por: Nwabufo, Chukwunonso K., et al.
Publicado: (2022)

Guilty, or not guilty?: a short story of propofol abuse
por: Lee, Sangseok
Publicado: (2013)

Genetic Evidence for Endolysosomal Dysfunction in Parkinson’s Disease: A Critical Overview
por: Yahya, Vidal, et al.
Publicado: (2023)

The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson’s Disease
por: Lin, Kai-Jung, et al.
Publicado: (2019)

Gastrointestinal Biopsies for the Diagnosis of Alpha-Synuclein Pathology in Parkinson's Disease
por: Cersosimo, Maria Graciela
Publicado: (2015)

Advances in understanding the function of alpha-synuclein: implications for Parkinson’s disease
por: Calabresi, Paolo, et al.
Publicado: (2023)

Pleading guilty /
por: Turow, Scott
Publicado: (1993)

The Guilty Mind
por: Bearcroft, John S.
Publicado: (1968)

Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
por: Gómez-Benito, Mónica, et al.
Publicado: (2020)

Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson’s Disease
por: König, Annekatrin, et al.
Publicado: (2018)

Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson’s Disease
por: Doppler, Kathrin
Publicado: (2021)

Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson’s Disease
por: Cardinale, Antonella, et al.
Publicado: (2021)

Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease: The Emerging Role of VDAC
por: Risiglione, Pierpaolo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a79qnitphakvtoaetl91lqhk4c